* Partnering negotiations ongoing for the Company's Ebola vaccine programs and PROSTVAC prostate cancer immunotherapy KVISTGAARD, Denmark, October 22, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today an update of its business activities and preliminary interim financial results for the first nine months of 2014. Ebola vaccine development and partnering The current Ebola outbreak in West Africa has spurred renewed interest in Bavarian Nordic's Ebola vaccine development as no approved vaccine or treatment exists. The Company has developed several vaccine candidates based on its proprietary vaccine platform technology, MVA-BN®, which in preclinical studies have shown the ability to offer protection against different species of the Ebola virus. One candidate is being accelerated into clinical development in collaboration with the U.S. National Institute of Allergy and Infectious Diseases with anticipated initiation of a trial in humans in 2015. The Company is now in advanced negotiations with a pharmaceutical company on a licensing and manufacturing agreement on its Ebola vaccine candidates. PROSTVAC Phase 3 study and partnering prospects Since Bavarian Nordic acquired the rights to PROSTVAC, it has been the Company's strategic focus to enter into a partnering agreement for commercialization of PROSTVAC. The PROSPECT Phase 3 clinical study is on track to complete enrollment of 1,200 patients before year end. Over the course of the study the Company has had partnering discussions with pharmaceutical companies. Several companies are currently showing interest in PROSTVAC and Bavarian Nordic is now in contract negotiations on partnering PROSTVAC. Current negotiations include upfront payment, milestone payments, and royalties on commercialization of PROSTVAC. However, at this time no assurance of a partnership agreement eventually being entered in to can be made. Preliminary interim financial results for the first nine months of 2014 The following consolidated financial statements for the period January 1 to September 30, 2014 are non-exhaustive and preliminary. The full financial statements for the period will be announced on November 13, 2014 as planned. The Company maintains its financial expectations for the full year with revenues in the level of DKK 1,200 million and a break-even result before interest and tax (EBIT). The Group's cash preparedness at year-end is expected to be approximately DKK 600 million. DKK million 1/1 - 30/9 2014 1/1 - 30/9 2013 -------------------------------------------------------------------------- un-audited un-audited Income statements Revenue 675.6 875.0 Production costs 328.1 346.8 Research and development costs 313.5 385.0 Distribution costs 34.3 27.4 Administrative costs 121.0 121.8 Income before interest and taxes (EBIT) (121.3) (6.0) Financial items, net 36.8 (11.7) Income before company tax (84.5) (17.7) Net profit for the period (72.0) (19.9) Cash Securities, cash and cash equivalents 236.1 426.0 Cash preparedness 356.1 546.0 Contacts Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone +45 61 77 47 43 Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654 About Bavarian Nordic Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial, and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. For more information, visit www.bavarian-nordic.com. About MVA-BN® MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) is a proprietary and patented vaccine platform technology of Bavarian Nordic. MVA-BN is a robust and adaptable platform suitable for addressing a wide variety of infectious diseases, including biological threats. In addition to developing MVA-BN as a safer smallpox vaccine (approved in the EU and Canada) essential to protecting the immune-compromised population, Bavarian Nordic has conducted more than a dozen preclinical and clinical studies of recombinant MVA-BN-based vaccines. More than 7,500 individuals, nearly 1,000 of whom are immunocompromised, have been vaccinated with MVA-BN-based vaccines, showing the platform displays high immunogenicity and a favorable safety profile. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. [HUG#1864687]
Bavarian Nordic Provides Update on Business Activities and
Top 10 Most Recent News Articles
Dolby's Strong Quarter Meets a Flat 2027 Reality Check
A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...
Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices
Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...
Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups
Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...
Continue Reading
Linux Foundation Unveils the Global Fraud Alliance
Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...
Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial
Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...
Continue Reading
ISDN Holdings: Leading APAC Automation with Innovation
Pioneering Automation Intelligence in APAC Not every day you hear a company quietly revolutionizing an entire industry's landscape—but ISDN Holdings Limited is one of those rare players. Recognized by Frost & Sullivan for its top-tier customer value leadership, ISDN is making waves across the Asia-Pacific's industrial scene with its integrated industrial automation...
Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027
New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...
Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games
A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...
Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts
Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...
Continue ReadingVeriSilicon's New AI/AR Glasses Tech: Game-Changer?
VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...
Continue ReadingTop 5 Most Recently Viewed Articles
S&P CoreLogic Case-Shiller Index Highlights Growth Trends
Overview of the Recent S&P CoreLogic Case-Shiller Index S&P Dow Jones Indices has released the results from its well-regarded S&P CoreLogic Case-Shiller Indices, revealing insightful trends in the U.S. housing market. The data indicates a notable 3.9% annual gain for December, reflecting a slight increase from previous figures earlier in the year. With over 27 years of...
Continue Reading
Baader Bank Enhances OTC Trading with New Extended Hours
Baader Bank Expands OTC Trading Hours MUNICH - Baader Bank AG, a prominent player in the German financial services sector, has recently announced a significant enhancement to its over-the-counter (OTC) trading hours. Starting today, clients can now engage in trading activities from 07:30 to 23:00. This extension is part of the bank's strategic initiative to bolster its...
Continue Reading
Nokia Strengthens Alliance with SoftBank Through Network Upgrade
Nokia Strengthens Alliance with SoftBank Through Network Upgrade Nokia has taken significant strides in enhancing its partnership with SoftBank Corp. through a new agreement focused on the modernization of network systems in Japan. This expansion involves the deployment of innovative 4G and 5G radio access solutions underpinned by Nokia's advanced AirScale portfolio....
Continue Reading
IS4S Launches Office to Enhance Regional Defense Solutions
IS4S Expands Operations with New Office Launch Integrated Solutions for Systems, Inc. (IS4S) has proudly announced the opening of its latest office, strategically situated to support its operations in New England. This new location enhances IS4S's capacity to engage with stakeholders associated with various Air Force programs, especially those managed by the Air Force...
Continue Reading
Discover the Future of Contract Management with CobbleStone
CobbleStone Software to Showcase Contract Management Solutions CobbleStone Software is set to exhibit its cutting-edge, AI-enhanced contract management solutions at an upcoming event, bringing together legal professionals from various sectors. This performance is part of the anticipated 2025 ACC Annual Meeting, where the company will engage with leaders in the legal...
Continue Reading